A new set of practice guidelines has been developed for the diagnosis and treatment of meningiomas using radiolabeled somatostatin receptor ligands. Meningiomas are common brain tumors, and these guidelines aim to standardize the use of advanced imaging techniques and targeted therapies.
Developed through a collaboration between the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and other key organizations, the guidelines focus on the use of positron emission tomography imaging. PET scans, which use SSTR ligands, can detect meningioma tissue with a high degree of sensitivity and specificity, offering important insights that traditional MRI and CT scans may not provide. This imaging technique is especially useful for diagnosing the extent of the tumor, distinguishing between scar tissue and tumor recurrence, and identifying bone involvement.
In addition to improving diagnosis, these guidelines also explore the potential of SSTR-targeted peptide receptor radionuclide therapy, an emerging treatment option for meningiomas. PRRT uses radiolabeled peptides to deliver targeted radiation directly to tumor cells.
The guidelines are designed to harmonize procedures across medical centers, making it easier to compare studies and build larger data sets. They will support both routine practice and clinical trials, helping to improve meningioma care worldwide.